Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Orexin antagonists like Idorsia’s Quviviq (daridorexant), Eisai’s Dayvigo (lemborexant) and MSD’s Belsomra (suvorexant) are already approved for insomnia itself, by J&J believes that ...

Quviviq was approved in the US last year, where it will have to go toe-to-toe in the marketplace with Merck's Belsomra (suvorexant) and Eisai's Dayvigo (lemborexant). It was due to be launched in ...